{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-171204","form_type":"8-K","ticker":"SPRY","cik":"0001671858","company_name":"ARS Pharmaceuticals, Inc.","filed_at":"2024-06-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.512985+00:00","generated_at":"2026-06-01T00:39:28.026128+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CHMP recommends EU marketing authorization for ARS Pharma's epinephrine nasal spray EURneffy","bullets":["CHMP adopted positive opinion for EURneffy (2 mg epinephrine nasal spray) for emergency anaphylaxis treatment.","Indicated for adults and children ≥30 kg; EC decision expected within 67 days of June 27, 2024.","EURneffy is a needle-free alternative to injectable epinephrine, potentially expanding treatment access.","Corporate presentation updated for investor meetings; no financial guidance changes reported."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-171204","json":"https://secwatch.observer/filing/0001193125-24-171204.json","markdown":"https://secwatch.observer/filing/0001193125-24-171204.md","text":"https://secwatch.observer/filing/0001193125-24-171204.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671858/000119312524171204/0001193125-24-171204-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671858/000119312524171204/d860381d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T00:39:28.026128+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}